Data / Federal rules / Prescription drugs
Federal rules on prescription drugs: 24 since January 2024
14 final rules and 10 proposed rules since January 11, 2024, 12 of them marked significant. 2 are open for comment now. Most come from the Centers for Medicare & Medicaid Services (11), Food and Drug Administration (5), Drug Enforcement Administration (4), Health and Human Services Department (4).
SpecStream is the live web data engine for teams and agents. It reads every rule and proposed rule in the Federal Register each morning, and this page is that reading. Name your industry once and new rules, comment deadlines and effective dates arrive in your sheet, CRM, Slack or agent as they are published.
Open for comment
Every document, newest first
| Document | Agency | Type | Published |
|---|
Nonclinical Testing Terminology
2026-19350 | Food and Drug Administration | Final rule | Sep 22 |
Nonclinical Testing Terminology
2026-19349 | Food and Drug Administration | Proposed rule | Sep 22 |
Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program
2026-14327 | Centers for Medicare & Medicaid Services | Proposed rule | Jul 16 |
Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
2026-13656 | Centers for Medicare & Medicaid Services | Proposed rule | Jul 7 |
Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
2026-12059 | Centers for Medicare & Medicaid Services | Proposed rule | Jun 16 |
Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
2026-11526 · significant | Drug Enforcement Administration | Final rule | Jun 9 |
Modification of Certain Terminology in Title 21
2026-08826 | Food and Drug Administration | Proposed rule | May 6 |
Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges
2026-07205 · significant | Centers for Medicare & Medicaid Services | Proposed rule | Apr 14 |
Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program; Correction
2026-04797 · significant | Centers for Medicare & Medicaid Services | Final rule | Mar 12 |
Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017
2026-02288 · significant | Drug Enforcement Administration | Final rule | Feb 5 |
Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
2025-24123 · significant | Health and Human Services Department | Final rule | Dec 31, 2025 |
Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program
2025-19787 · significant | Centers for Medicare & Medicaid Services | Final rule | Nov 5, 2025 |
Controlled Substances Ordering System (CSOS) Modernization
2025-19325 | Drug Enforcement Administration | Final rule | Oct 2, 2025 |
Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program
2025-13271 · significant | Centers for Medicare & Medicaid Services | Proposed rule | Jul 16, 2025 |
Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments; and Appeal Rights for Certain Changes in Patient Status; Corrections and Correcting Amendment
2025-08676 | Centers for Medicare & Medicaid Services | Final rule | May 16, 2025 |
Special Registrations for Telemedicine and Limited State Telemedicine Registrations
2025-01099 · significant | Drug Enforcement Administration | Proposed rule | Jan 17, 2025 |
Expansion of Buprenorphine Treatment via Telemedicine Encounter
2025-01049 · significant | Health and Human Services Department | Final rule | Jan 17, 2025 |
Continuity of Care via Telemedicine for Veterans Affairs Patients
2025-01044 · significant | Health and Human Services Department | Final rule | Jan 17, 2025 |
Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments
2024-25382 · significant | Centers for Medicare & Medicaid Services | Final rule | Dec 9, 2024 |
Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments
2024-14828 | Centers for Medicare & Medicaid Services | Proposed rule | Jul 31, 2024 |
Current Good Manufacturing Practice, Certification, Postmarketing Safety Reporting, and Labeling Requirements for Certain Medical Gases
2024-13190 | Food and Drug Administration | Final rule | Jun 18, 2024 |
Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act
2024-05801 | Food and Drug Administration | Proposed rule | Mar 20, 2024 |
Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges, Merit-Based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
2024-00895 · significant | Centers for Medicare & Medicaid Services | Final rule | Feb 8, 2024 |
Safeguarding the Rights of Conscience as Protected by Federal Statutes
2024-00091 | Health and Human Services Department | Final rule | Jan 11, 2024 |
Other topics
Read from the Federal Register API, last updated 2026-10-23. The document on federalregister.gov is the official record; dates and dockets can change through later corrections. Free to reuse with credit to SpecStream under CC BY 4.0.